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It is becoming apparent that infections by a major class of viruses, those with envelopes, can be inhibited
during their entry at the step of fusion with cellular membranes. In this review, we discuss multiple innate
immune mechanisms that have evolved to modify the lipid composition of cellular and viral membranes to
inhibit virion fusion of enveloped viruses.Introduction
Host cells have evolved numerous innate defenses against virus
infection, including a collection of constitutively expressed anti-
viral restriction factors and a variety of specialized responses
induced by viral infection. A major component of the induced
innate immune response to viral infections is theactivationof anti-
viral interferons (IFNs),which transcriptionally inducehundredsof
interferon-stimulated genes (ISGs). ISGs have varied functions,
including regulating the IFN response or, alternatively, encoding
effector molecules that directly inhibit viral infection. Collectively,
the ISG response facilitates clearance of virus from infected cells,
establishes a protective antiviral state in uninfected cells, and
promotes adaptive immune responses (Samuel, 2001).
ISGs are induced across numerous cell types and species;
however, their functional characterization has been relatively
limited.The ISG functions that havebeencharacterized frequently
target conserved aspects of virus infections. This includes ISGs
that impact the integrity of nucleic acids, such as the 20,50-oligoi-
soadenylate synthetase (OAS) and ribonuclease (RNase) L
pathway, adenosine deaminase RNA-specific (ADARs), and
apiloprotein B mRNA editing enzyme catalytic polypeptides
(APOBECs); protein translation, such as protein kinase R (PKR);
and virion budding, such as bone marrow stromal cell antigen 2
(BST2)/Tetherin (Sadler andWilliams, 2008). Functional screening
approaches, including ISG overexpression and knockdown
screens, have been used to catalog a broader range of putative
IFN-induced antiviral effectors (Ablasser and Hornung, 2013;
Fusco et al., 2013; Karki et al., 2012; Liu et al., 2012; Metz et al.,
2012; Schoggins et al., 2011; Zhao et al., 2012). The respective
functions of these newly defined antiviral effector ISGs will likely
target an expanding repertoire of virus-host interactions.
Lipids facilitate all stages of the viral life cycle, including initial
interactions of the virion with the host cell, envelope fusion,
modification of cellular membranes to establish sites of replica-
tion and/or assembly, cellular metabolism, and the coordination
of virion assembly and budding (reviewed in Heaton and Randall,
2011). As such, they are attractive targets for innate immune
defenses and the development of therapeutics. For example,
many viruses require fatty acid biosynthesis for their replication
and assembly (reviewed in Chukkapalli et al., 2012). AMP kinase,
which is not an ISG, limits viral replication by inhibiting the rate-
limiting enzyme in fatty acid biosynthesis, acetyl coenzyme A
(CoA) carboxylase (Moser et al., 2012). Indeed, one of the
more extensively characterized ISGs, viperin, canmodulate virusinfections by impacting lipids in multiple ways. Human cytomeg-
alovirus (HCMV) co-opts viperin to inhibit lipid b-oxidation, which
in turn stimulates lipid biogenesis that supports virion envelop-
ment. Viperin also inhibits isoprenoid synthesis, which disrupts
lipid rafts and, in turn, limits virus infection that requires lipid rafts
for virus entry or budding (reviewed in Seo et al., 2011).
A major lipid-dependent interaction in enveloped virus infec-
tion is the fusion of the virion lipid bilayer with a cellular mem-
brane to release the viral genome into the cytoplasm (reviewed
in Plemper, 2011). This can occur either at the plasmamembrane
or at distinct endosomal compartments, governed in part by the
pH dependence of the viral fusion apparatus. Generically, fusion
occurs when the interaction of the viral envelope protein(s) with
the host cell produces conformational changes in the viral fusion
protein that expose its fusion peptide and generate sufficient free
energy to facilitatemembrane fusion, which is inherently an ener-
getically unfavorable event. In the case of viruses that fuse at the
plasmamembrane, conformational changes in the fusion protein
that occur after receptor engagement are sufficient to drive
fusion. For viruses that fuse in endosomal compartments, pro-
tonation of the fusion protein that occurs with acidifying endo-
cytic pH frequently promotes fusion. Additionally, endosomal
or lysosomal proteases that cleave the fusion protein or, alterna-
tively, endosomal lipids and/or protein receptors can promote
the fusion process (Plemper, 2011). Once the fusion protein
has positioned the viral envelope in close proximity to the cellular
membrane, hemifusion, in which the outer leaflets of the viral and
cellular lipid bilayers fuse, can occur (Figure 1A). Following
hemifusion, an early fusion pore forms, which then enlarges to
a late fusion pore through which the viral nucelocapsid is
released into the cytoplasm. Important for this review, the fusion
process, and hemifusion in particular, is sensitive to the lipid
composition of membranes, which affects membrane curvature
and fluidity (Figure 1B). As such, the modulation of membrane
lipid composition is a viable approach to inhibit virion fusion. In
this review, we discuss a number of recent discoveries that char-
acterize host restriction of viral infection, especially virion fusion,
by modifying pathways that synthesize, process, or transport
lipids to alter membrane composition.
Interferon Modulates Sterol Biosynthesis and
25-Hydroxycholesterol
In a recent study, microarray profiling of macrophages either
treated with IFN-g or infected with murine cytomegalovirusCell Host & Microbe 14, October 16, 2013 ª2013 Elsevier Inc. 379
Figure 1. Model for Lipid Modulation of Membrane Fusion
(A) Viral fusion proteins (not shown) bring membranes in close apposition, thus
promoting hairpin formation. Hemifusion then occurs, wherein the outer leaf-
lets of each bilayer fuse and produce a stalk conformation induced by negative
membrane curvature. This elongates into a diaphragm conformation in which
the inner leaflets align, followed by pore formation, which results in the delivery
of the nucleocapsid to the cytoplasm.
(B) Lipids that promote negative membrane curvature or membrane fluidity,
such as PE and cholesterol, can facilitate fusion, while lipids that promote
positive curvature or rigidity are inhibitory to fusion (reviewed in Teissier and
Pe´cheur, 2007). *Fatty acid hydroxylation by LJ001.
Figure 2. Intersection of Interferon Signaling and the Mevalonate
Branch of Sterol Biosynthesis
Mevalonate synthesis has multiple downstream effects, including cholesterol
synthesis, protein prenylation and geranylgeranylation, and synthesis of do-
lichols, other sterols, heme A, and ubiquinones (not shown). Cholesterol can
be converted to 25-hydroxycholesterol by CH25H. Virus-mediated interferon
induction leads to synthesis of CH25H in macrophages. Putative antiviral
mechanisms (dashed red line) of 25HC include direct effects on virion fusion to
the host cell and indirect effects mediated by modulation of SREBP2 target
genes. Select SREBP2 target genes (green arrow) are shown in italics.
Cell Host & Microbe
Short Review(mCMV) identified repression of the sterol biosynthetic pathway
as a significant component of IFN antiviral effects (Blanc et al.,
2011). The consequence of repressed sterol biosynthetic gene
expression was a reduction in levels of cellular cholesterol. The
class of drugs known as statins impairs cholesterol synthesis
by inhibiting HMG-CoA reductase, an enzyme required for syn-
thesis of the cholesterol intermediate mevalonate. Cells treated
with simvastatin were resistant to mCMV, and culturing cells
with mevalonate, but not cholesterol, reversed this resistance.
The silencing of either Hmgcs1 or Hmgcr, two genes encoding
enzymes in sterol biosynthesis, resulted in decreased mCMV
infection. Collectively, these studies point to a role for the prox-
imal mevalonate arm of sterol biosynthesis, but not cholesterol
itself, in regulating mCMV infection (Figure 2). The authors
hypothesize a requirement for the prenylation of viral and/or
cellular proteins in mCMV infection. The repression of sterol
biosynthesis by IFN appears to occur via the reduced expression
of sterol regulatory element binding protein 2 (SREBP2), a tran-380 Cell Host & Microbe 14, October 16, 2013 ª2013 Elsevier Inc.scriptional regulator of sterol biosynthesis. mCMV-infected
mice treated with simvastatin had 1- to 1.5-log reductions in viral
titers in spleen, liver, kidney, heart, and lungs.
Further studies probing the antiviral mechanisms underlying
these observations have defined a role for the oxysterol 25-hy-
droxycholesterol (25HC) as an antiviral sterol-lipid effector.
25HC is one of several naturally occurring oxysterols that are
derived from cholesterol and contain a hydroxyl group on the
side chain. Cholesterol 25-hydroxylase (Ch25h in mice, CH25H
in humans) catalyzes the synthesis of 25HC from cholesterol.
CH25H and 25HC are increasingly implicated in modulating
host immunity at multiple levels. For example, 25HC has been
shown to suppress the production of immunoglobulin A (IgA)
by B cells, and Ch25h/ mice have increased IgA levels in
serum (Bauman et al., 2009). 25HC has also been implicated in
suppressing the differentiation of monocytes to macrophages
(Ecker et al., 2010). Dendritic cells and macrophages upregulate
CH25H in response to type I IFNs, suggesting a potential role for
25HC in innate immunity (Park and Scott, 2010).
An overexpression screen designed to identify IFN-induced
antiviral effectors uncovered an antiviral role for CH25H (Liu
et al., 2012). Ectopic expression of CH25H in 293T cells
conferred a strong antiviral effect against two enveloped viruses:
the DNA virus murine gamma herpesvirus 6 (MHV68) and the
RNA virus vesicular stomatitis virus (VSV). In a follow-up study,
the same group characterized the mechanisms of CH25H anti-
viral activity (Liu et al., 2013). They used either shRNA-mediated
knockdown of Ch25h or cells from Ch25h/ mice to show that
optimal control of VSV replication required Ch25h. In a series of
media transfer experiments, it was demonstrated that CH25H
expression produces a soluble antiviral factor that was not
type I IFN. Thus, the authors examined the natural product of
CH25H activity, 25HC. Indeed, exogenous addition of 25HC to
cells suppressed VSV infection. Remarkably, a pan-antiviral
Figure 3. Model for Innate Antiviral Responses that Modify Lipid
Compostition
Virus infection triggers multiple innate immune defenses modulating mem-
brane composition, including IFITM3 homodimer formation and IFITM3 tar-
geting of VAPA to LE and MVB to increase their cholesterol and LBPA levels,
CH25H expression at the ER for 25HC synthesis and secretion, and plasma
membrane accumulation of LRP1 to decrease intracellular cholesterol. This
prevents virion hemifusion in endosomal compartments by modulating the
lipid composition of viral and cellular membranes. EE, early endosome.
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viruses including HIV-1, MHV68, herpes simplex virus 1 (HSV-1),
ebolavirus, Rift Valley fever virus, and Nipah virus. 25HC had no
effect on the nonenveloped adenovirus, suggesting that the anti-
viral effects may be specific to enveloped viruses, although other
nonenveloped viruses remain to be characterized. The antiviral
potency of 25HC was variable depending on the virus, with
effects on viral titers ranging from 2-fold to more than 10-fold.
The antiviral effects of 25HC on VSV infection were selective
relative to other oxysterols and independent of other known
25HC functions, including the regulation of SREBP2,mevalonate
production, or protein prenylation (Liu et al., 2013).
25HC did not impair VSV or HIV binding, but rather inhibited
virus-cell fusion by affecting some property of the cellular mem-
brane. In a cell-cell membrane fusion assay using only the Nipah
virus fusion (F) and attachment (G) proteins, 25HC was shown to
reduce syncytia formation. This surrogate assay suggests that
similar mechanisms may be operating at the viral-host mem-
brane interface. The antiviral effect of 25HC on VSV could be
competed by incubating the 25HC-containing VSV inoculum
with artificial liposomes containing lipid content similar to cellular
membranes. These rescue experiments further suggest that
25HC directly alters cellular membranes, thereby interfering
with virus entry (Figure 3). Lastly, 25HC inhibited HIV in a human-
izedmousemodel, andCh25h/miceweremore susceptible to
MHV68 than wild-type mice were, thereby solidifying the impor-
tance of this oxysterol pathway in innate antiviral immunity in vivo
(Liu et al., 2013).
25HC was also uncovered as an IFN-induced antiviral mole-
cule using a distinct metabolomics approach (Blanc et al.,
2013). Liquid chromatography-mass spectrometry (LC-MS)
analysis of oxysterols selectively identified 25HC as upregulated
by mouse macrophages after either viral infection or IFN treat-
ment. Similar to the results by Liu et al. (2013), the authors
demonstrated that exogenous 25HC had antiviral effects againsta panel of enveloped viruses, but no effect on adenovirus. To
dissect the selectivity of 25HC, an enantiomer of 25HC, ent-
25HC, was tested for effects on viral growth. This compound
was also able to suppress viral infection, but only at high concen-
trations. The authors conclude that the enantioselectivity of
25HC antiviral action may suggest additional membrane-inde-
pendent functions of 25HC. Although HSV-1 entry was inhibited
by 25HC, other enveloped viruses were inhibited by 25HC at
postentry steps. 25HC treatment of cells infected with mCMV,
influenza A virus (IAV), or MHV68 resulted in a small plaque
phenotype, whereas the total number of plaques was not
impacted by 25HC. Thus, 25HC likely does not affect the infec-
tivity of the viral inoculum, but rather impairs the ability of the
virus to spread. This result is indicative of a postentry inhibition
of these virus infections, possibly at the stage of cell-cell spread,
as was shown by the authors for varicella zoster virus infection.
The somewhat different conclusions of the two studies with re-
gards to 25HC mechanism of action may represent differences
in experimental conditions. For example, Blanc et al. (2013)
used delipidated media in their studies, while Liu et al. (2013)
used normal serum-complemented media. The differential
effects of these media formulations in the context of antiviral
mechanisms are unclear. Nonetheless, it is likely that 25HC
can exert antiviral activity at multiple stages of the viral life cycle.
In the case of mCMV infection, evidence was presented for both
SREBP-dependent and SREBP-independent modes of 25HC
antiviral action. Both studies implicate additional postentry roles
for 25HC, including inhibition of virus-induced cell-cell fusion
(syncytia formation) and virus spread. Additionally, 25HC has
been found to interfere with the replication of HCV, possibly by
altering the lipid composition of membranous replication com-
partments or protein prenylation (Pezacki et al., 2009). Similar
mechanisms may be responsible for 25HC effects on viruses
such as mCMV. Thus, 25HC has the attributes to modulate virus
infections at many levels.
Interferon-Inducible Transmembrane Proteins 1–3
Interferon-inducible transmembrane proteins (IFITMs) 1–3 are
part of a family of structurally related proteins that have basal
expression in many cell types but are induced to higher levels
of expression by IFNs. The various IFITMs exhibit inhibitory ac-
tivity against multiple enveloped viruses prior to fusion, with their
commonality being that the subset of inhibited viruses appears
to share the same cellular location for virion fusion (reviewed in
Diamond and Farzan, 2013). For example, IFITM3 inhibits the
fusion of influenza A virus (IAV), dengue virus, and West Nile
viruse, which fuse at the late endosome (LE), while IFITM1 pref-
erentially inhibits ebolavirus and severe acute respiratory syn-
drome (SARS) coronavirus, which fuse at the lysosome (Brass
et al., 2009; Feeley et al., 2011; Huang et al., 2011). IFITM3 is
particularly important for the control of IAV in vivo. IFITM3
knockout mice have enhanced pathology following IAV infection
(Bailey et al., 2012). In humans, a rare IFITM3 allele with reduced
anti-iAV efficacy has been identified in hospitalized patients pre-
senting with severe influenza (Bailey et al., 2012; Everitt et al.,
2012). IFITMs generally do not restrict viral fusion at the plasma
membrane or recycling endosome. In support of a model
wherein the site of fusion determines IFITM antiviral activity,
SARS coronavirus, which is typically restricted by IFITM1,Cell Host & Microbe 14, October 16, 2013 ª2013 Elsevier Inc. 381
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enable plasma membrane fusion (Huang et al., 2011). IFITM pro-
teins primarily localize to cytosolic vesicles, including LEs. These
data have led to the hypothesis that IFITMsmaymodify either the
pH or lipid composition of LEs and lysosomes to render them
resistant to fusion. IFITMs, particularly IFITM1, can also localize
to the plasma membrane following overexpression or interferon
induction. Thus, IFITM1 can also efficiently inhibit cell-cell fusion
(syncytia formation), HCV coreceptor interactions, and HIV repli-
cation at a postentry step (Li et al., 2013; Lu et al., 2011; Wilkins
et al., 2013).
It was recently proposed that IFITMs inhibit viral hemifusion (Li
et al., 2013). IFITM1, IFITM2, or IFITM3 expression blocked cell
membrane hemifusion induced by all classes of viral fusion
proteins. Altering the membrane composition with oleic acid,
which induces negative membrane curvature favorable to hemi-
fusion, overcame IFITM-mediated restriction of cell fusion. IFITM
expression alters the biophysical properties of membranes. The
membranes of IFITM-expressing cells have increased lipid
packing (and thus decreased fluid dynamics), as assessed
by fluorescence polarization approaches (Li et al., 2013). This
alteration in membrane fluidity would inhibit hemifusion by
increasing the free energy required to induce negative mem-
brane curvature.
The mechanism by which IFITM3 prevents hemifusion has
been proposed to require both homo- and heteromeric interac-
tions. Mapping of IFITM3 topology using sites for posttransla-
tional modifications suggests a model wherein the N and C
termini are cytosolic and flank two intramembranous domains
that are separated by a conserved cytosolic loop (Yount et al.,
2012). The first intramembranous domain plus the conserved
cytosolic loop compromise a CD225 domain, which is present
in over 300 proteins. Mutagenesis studies show that the N-termi-
nal cytosolic domain and the CD225 domain are essential for
IFITM3 function (John et al., 2013). Amino acids in the intramem-
branous portion of the CD225 domain are required for IFITM
self-association, leading to a model wherein IFITM3 homomeric
interactions alter endosomal membrane fluidity and curvature
(Figure 3).
Additionally, IFITM mechanism of action involves perturbation
of intracellular lipid transport (Amini-Bavil-Olyaee et al., 2013).
Vesicle-associated membrane protein (VAMP)-associated
protein A (VAPA) was identified as an IFITM3-interacting protein
using the yeast two-hybrid system. VAPA interacts with oxy-
sterol-binding protein (OSBP) to transfer cholesterol from
the endoplasmic reticulum (ER) to organelles and vesicles.
IFITM1–IFITM3 all bind VAPA via the second transmembranous
domain, and the binding of IFITM3 to VAPA interferes with the
VAPA-OSBP interaction. IFITM3 overexpression altered cellular
cholesterol levels, with increased accumulation of cholesterol
and lysobisphosphatidic acid (LBPA) in LE and multivesicular
body (MVB) compartments. Increased endosomal cholesterol
and LBPA can perturb virion fusion (Chevallier et al., 2008).
The IFITM3-VAPA interaction appeared to be important for inhi-
bition of VSV and IAV entry. In the case of VSV infection, IFITM3
expression resulted in the accumulation of VSV in MVBs during
the entry process, suggestive of a block in fusion. The authors
propose a model wherein IFITMs bind VAPA and recruit it to
endosomal compartments to transfer cholesterol and LBPA,382 Cell Host & Microbe 14, October 16, 2013 ª2013 Elsevier Inc.creating a lipid environment that is resistant to virion fusion
(Figure 3).
Low-Density Lipoprotein-Related Receptor 1
Low-density lipoprotein-related receptor 1 (LRP1) is an antiviral
host protein that modulates virion lipid composition to impact
the efficiency of viral fusion (Gudleski-O’Regan et al., 2012). It
is a ubiquitously expressed plasma membrane protein that
regulates cholesterol efflux and import. Its accumulation at the
plasma membrane is transiently increased following HCMV
infection and is associated with decreased intracellular choles-
terol. Inhibition of LRP1 expression or function elevated intracel-
lular cholesterol and enhanced infectious HCMV production
(Gudleski-O’Regan et al., 2012). This effect is due to increased
cholesterol in HCMV virions, leading to an enhanced specific
infectivity. It was speculated that this increased infectivity is
due to enhanced fusion, sinceHCMV fusion requires cholesterol.
Taken together, the data suggest that LRP1 is induced shortly
after infection to decrease intracellular cholesterol, thus altering
the lipid composition of viral envelopes and decreasing their
subsequent fusion capacity in a second round of infection
(Figure 3).
Lipid Modulation as an Approach for Broad-Spectrum
Antivirals
A number of compounds have been identified as potential
broad-spectrum inhibitors of enveloped viruses. The proposed
mechanisms of action for these compounds target different
aspects of the fusion process. One of the better studied com-
pounds is Arbidol, which is approved for influenza A and B virus
treatment in Russia and China and has been proposed to modu-
late fusion protein interaction with phospholipids to prevent pro-
tein conformational changes required for fusion (Teissier et al.,
2011). Squalamine, a cationic amphipathic sterol isolated from
the dogfish shark, has antiviral activity in vitro and in vivo. It
also has affinity for phospholipids and may perturb the fusion
process (Zasloff et al., 2011).
The inhibition of viral fusion by modulating membrane lipid
composition underscores the importance of the biophysical
properties of virion envelopes for fusion. One antiviral approach
is to design small molecules that resemble fusion inhibitory lyso-
phospholipids. Synthetic compounds called rigid amphipathic
fusion inhibitors (RAFIs), which are designed to physically
resemble lysophospholipids, also show promise in inhibiting
fusion with improved toxicity and pharmacokinetic profiles
(St Vincent et al., 2010). These compounds insert into mem-
branes and are predicted to produce positive membrane curva-
ture in the outer leaflets, thereby inhibiting hemifusion. LJ001, a
rhodanine derivative that is chemically distinct from RAFIs, also
inhibits the replication of enveloped viruses by targeting the
membrane component (Wolf et al., 2010). Interestingly, its mech-
anism of action is not simply based on mimicking a lipid shape,
such as lysophosphatidylcholine (LPC). It intercalates lipid
bilayers and acts as a photosensitizer, hydroxylating the fatty
acid chains of unsaturated phospholipids (Vigant et al., 2013).
This alters the physical properties of membranes, resulting in
the inhibition of virion fusion.
Yet another approach to alter lipid composition for viral entry
inhibition is to target cellular lipid synthesis or uptake pathways.
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receptor expressed on hepatocytes and enterocytes. Inhibition
of its cholesterol uptake activity with the FDA-approved drug
ezetimibe blocks HCV and HBV infection (Lucifora et al., 2013;
Sainz et al., 2012). In the case of HCV, it inhibits entry prior to
completion of fusion, in a cholesterol-dependent manner,
although the specific mechanism of action is undefined (Sainz
et al., 2012).
The inhibition of sterol biosynthesis also has potential for anti-
viral therapy. In particular, statins are generally well tolerated in
patients and have broad-spectrum antiviral activity in vitro.
Accumulating evidence suggests that they have some efficacy
in treating HCV and IAV infections, either via antiviral activity or
immunomodulatory effects (reviewed in Sheridan et al., 2013;
Walsh, 2012).
Remaining Questions and New Roles for Lipids in the
Antiviral Response
As the discoveries of these antiviral mechanisms that primarily
target fusion are quite recent, many questions and exciting ave-
nues for research remain. In the case of 25HC, at least four major
questions remain. (i) As a secreted oxysterol that can permeate
membranes, what is the primary target membrane to inhibit
virion fusion? Since entry has already occurred in the infected
cell, two nonexclusive possibilities remain: modification of
neighboring cellular membranes in a paracrine manner or, alter-
natively, directly neutralizing intra- or extracellular virions. (ii)
What is the chemical basis of 25HC fusion inhibition? Options
include the exclusion of cholesterol and alterations of membrane
fluid dynamics by 25HC lipid packing properties. (iii) What are the
mechanisms of postfusion 25HC antiviral activity? As lipids are
required at virtually every stage of the viral life cycle, there are
multiple potential intervention points. Additionally, 25HC regu-
lates sterol biosynthesis at multiple stages, suggesting potential
indirect roles in antiviral regulation. (iv) 25HC has been shown to
regulate both the innate and adaptive immune responses. How
does 25HC integrate the two arms of the immune system to
orchestrate an effective antiviral response? Given that LJ001
functions by hydroxylating fatty acid chains, one wonders
whether increasing the hydroxylated lipid content in membranes
is a more general approach to inhibiting viral fusion.
In the case of IFITMs, a remaining question is the basis for the
differing antiviral properties of IFITM1–IFITM3. Do they individu-
ally recruit VAPA to distinct endosomal compartments? Do
ISGs modulate lipid composition at other locations, such as
the plasma membrane, to inhibit viral fusion? Finally, although
most IFITM studies have focused on fusion, it remains possible
that theymay also inhibit subsequent events in the viral life cycle.
The lipid composition of intracellular organelles is likely impor-
tant for membrane remodeling to establish sites of replication
for positive strand RNA viruses. HCV interacts with VAPA and
requires VAPA andOSBP for its replication. Additionally, multiple
viruses access MVBs as part of their egress and may be
impacted by IFITMs. The inhibition of later stages of the viral
life cycle would provide an antiviral role for IFN induction of
IFITMs within the infected cell and not just in establishing an
environment that is resistant to viral entry in naive cells.
Multiple questions remain regarding the role of LRP1 in viral in-
fections. It is not clear what elevates LRP1 plasma membranelevels following HCMV infection and whether this is regulated
by the IFN response. Although it was not investigated whether
LRP1 alters the infectivity of other enveloped viruses, LRP1 is
upregulated by HIV infection of T cells and in monocytes of
long-term nonprogressors, suggesting that it may have broad-
spectrum antiviral activity (Rasheed et al., 2008; Stebbing
et al., 2003).
Finally, we anticipate an expanding appreciation of the roles
of lipids in the antiviral response to infection, in terms of both
directly inhibiting viral infection and regulating the adaptive and
inflammatory responses. As an example, bioactive lipids from
the 12/15 lipoxygenase pathway have recently been discovered
to modulate IAV infection. Omega-3 polyunsaturated fatty acid
(PUFA) lipid mediator D1 (PD1) inhibits IAV infection in cell cul-
ture (Morita et al., 2013). It acts at the stage of early gene expres-
sion, preventing the export of viral messenger and genomic
RNAs by inhibiting their interaction with the nuclear export factor
NXF1 by an unknownmechanism. PD1 levels are decreased dur-
ing IAV infection in vivo, and its expression inversely correlates
with disease severity. Tam et al. (2013) also identified 12/15
lipoxygenase-derived metabolites that differentially accumulate
in response to IAV infection in vivo. Importantly, their accumula-
tion correlates with both antiviral activity and resolution of inflam-
mation. PD1 administration in IAV lung infection in mice reduced
viral titers and improved survival, suggesting therapeutic
potential. Thus, lipids have multiple roles in antiviral innate and
adaptive responses, in control of inflammation, and potentially
in the development of antiviral therapeutics.
ACKNOWLEDGMENTS
We thank David Russell and Vineela Chukkapalli for helpful discussions.
Unfortunately, due to space limitations, wewere unable to cite all relevant liter-
ature and apologize to those omitted. G.R. is supported by NIAID (AI080703
and AI102236), the American Cancer Society (118676-RSG-10-059-01-
MPC), and Susan and David Sherman. J.W.S. is supported by NIDDK
(DK095031).
REFERENCES
Ablasser, A., and Hornung, V. (2013). DNA sensing unchained. Cell Res. 23,
585–587.
Amini-Bavil-Olyaee, S., Choi, Y.J., Lee, J.H., Shi, M., Huang, I.C., Farzan, M.,
and Jung, J.U. (2013). The antiviral effector IFITM3 disrupts intracellular
cholesterol homeostasis to block viral entry. Cell Host Microbe 13, 452–464.
Bailey, C.C., Huang, I.C., Kam, C., and Farzan, M. (2012). Ifitm3 limits the
severity of acute influenza in mice. PLoS Pathog. 8, e1002909.
Bauman, D.R., Bitmansour, A.D., McDonald, J.G., Thompson, B.M., Liang, G.,
and Russell, D.W. (2009). 25-Hydroxycholesterol secreted by macrophages in
response to Toll-like receptor activation suppresses immunoglobulin A pro-
duction. Proc. Natl. Acad. Sci. USA 106, 16764–16769.
Blanc, M., Hsieh, W.Y., Robertson, K.A., Watterson, S., Shui, G., Lacaze, P.,
Khondoker, M., Dickinson, P., Sing, G., Rodrı´guez-Martı´n, S., et al. (2011).
Host defense against viral infection involves interferon mediated down-regula-
tion of sterol biosynthesis. PLoS Biol. 9, e1000598.
Blanc, M., Hsieh, W.Y., Robertson, K.A., Kropp, K.A., Forster, T., Shui, G.,
Lacaze, P., Watterson, S., Griffiths, S.J., Spann, N.J., et al. (2013). The tran-
scription factor STAT-1 couples macrophage synthesis of 25-hydroxycholes-
terol to the interferon antiviral response. Immunity 38, 106–118.
Brass, A.L., Huang, I.C., Benita, Y., John, S.P., Krishnan, M.N., Feeley, E.M.,
Ryan, B.J., Weyer, J.L., van der Weyden, L., Fikrig, E., et al. (2009). The IFITM
proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus,
and dengue virus. Cell 139, 1243–1254.Cell Host & Microbe 14, October 16, 2013 ª2013 Elsevier Inc. 383
Cell Host & Microbe
Short ReviewChevallier, J., Chamoun, Z., Jiang, G., Prestwich, G., Sakai, N., Matile, S.,
Parton, R.G., and Gruenberg, J. (2008). Lysobisphosphatidic acid controls
endosomal cholesterol levels. J. Biol. Chem. 283, 27871–27880.
Chukkapalli, V., Heaton, N.S., and Randall, G. (2012). Lipids at the interface of
virus-host interactions. Curr. Opin. Microbiol. 15, 512–518.
Diamond, M.S., and Farzan, M. (2013). The broad-spectrum antiviral functions
of IFIT and IFITM proteins. Nat. Rev. Immunol. 13, 46–57.
Ecker, J., Liebisch, G., Englmaier, M., Grandl, M., Robenek, H., and Schmitz,
G. (2010). Induction of fatty acid synthesis is a key requirement for phagocytic
differentiation of human monocytes. Proc. Natl. Acad. Sci. USA 107, 7817–
7822.
Everitt, A.R., Clare, S., Pertel, T., John, S.P., Wash, R.S., Smith, S.E., Chin,
C.R., Feeley, E.M., Sims, J.S., Adams, D.J., et al.; GenISIS Investigators;
MOSAIC Investigators. (2012). IFITM3 restricts the morbidity and mortality
associated with influenza. Nature 484, 519–523.
Feeley, E.M., Sims, J.S., John, S.P., Chin, C.R., Pertel, T., Chen, L.M., Gaiha,
G.D., Ryan, B.J., Donis, R.O., Elledge, S.J., and Brass, A.L. (2011). IFITM3
inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog.
7, e1002337.
Fusco, D.N., Brisac, C., John, S.P., Huang, Y.W., Chin, C.R., Xie, T., Zhao, H.,
Jilg, N., Zhang, L., Chevaliez, S., et al. (2013). A genetic screen identifies inter-
feron-a effector genes required to suppress hepatitis C virus replication.
Gastroenterology 144, 1438–1449, e1–e9.
Gudleski-O’Regan, N., Greco, T.M., Cristea, I.M., and Shenk, T. (2012).
Increased expression of LDL receptor-related protein 1 during human cyto-
megalovirus infection reduces virion cholesterol and infectivity. Cell Host
Microbe 12, 86–96.
Heaton, N.S., and Randall, G. (2011). Multifaceted roles for lipids in viral infec-
tion. Trends Microbiol. 19, 368–375.
Huang, I.C., Bailey, C.C., Weyer, J.L., Radoshitzky, S.R., Becker, M.M.,
Chiang, J.J., Brass, A.L., Ahmed, A.A., Chi, X., Dong, L., et al. (2011). Distinct
patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and
influenza A virus. PLoS Pathog. 7, e1001258.
John, S.P., Chin, C.R., Perreira, J.M., Feeley, E.M., Aker, A.M., Savidis, G.,
Smith, S.E., Elia, A.E., Everitt, A.R., Vora, M., et al. (2013). The CD225 domain
of IFITM3 is required for both IFITM protein association and inhibition of influ-
enza A virus and dengue virus replication. J. Virol. 87, 7837–7852.
Karki, S., Li, M.M., Schoggins, J.W., Tian, S., Rice, C.M., andMacDonald,M.R.
(2012). Multiple interferon stimulated genes synergize with the zinc finger anti-
viral protein to mediate anti-alphavirus activity. PLoS ONE 7, e37398.
Li, K., Markosyan, R.M., Zheng, Y.M., Golfetto, O., Bungart, B., Li, M., Ding, S.,
He, Y., Liang, C., Lee, J.C., et al. (2013). IFITM proteins restrict viral membrane
hemifusion. PLoS Pathog. 9, e1003124.
Liu, S.Y., Sanchez, D.J., Aliyari, R., Lu, S., and Cheng, G. (2012). Systematic
identification of type I and type II interferon-induced antiviral factors. Proc.
Natl. Acad. Sci. USA 109, 4239–4244.
Liu, S.Y., Aliyari, R., Chikere, K., Li, G., Marsden, M.D., Smith, J.K., Pernet, O.,
Guo, H., Nusbaum, R., Zack, J.A., et al. (2013). Interferon-inducible choles-
terol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxy-
cholesterol. Immunity 38, 92–105.
Lu, J., Pan, Q., Rong, L., He, W., Liu, S.L., and Liang, C. (2011). The IFITM
proteins inhibit HIV-1 infection. J. Virol. 85, 2126–2137.
Lucifora, J., Esser, K., and Protzer, U. (2013). Ezetimibe blocks hepatitis B virus
infection after virus uptake into hepatocytes. Antiviral Res. 97, 195–197.
Metz, P., Dazert, E., Ruggieri, A., Mazur, J., Kaderali, L., Kaul, A., Zeuge, U.,
Windisch, M.P., Trippler, M., Lohmann, V., et al. (2012). Identification of type
I and type II interferon-induced effectors controlling hepatitis C virus replica-
tion. Hepatology 56, 2082–2093.
Morita, M., Kuba, K., Ichikawa, A., Nakayama, M., Katahira, J., Iwamoto, R.,
Watanebe, T., Sakabe, S., Daidoji, T., Nakamura, S., et al. (2013). The lipid
mediator protectin D1 inhibits influenza virus replication and improves severe
influenza. Cell 153, 112–125.384 Cell Host & Microbe 14, October 16, 2013 ª2013 Elsevier Inc.Moser, T.S., Schieffer, D., and Cherry, S. (2012). AMP-activated kinase
restricts Rift Valley fever virus infection by inhibiting fatty acid synthesis.
PLoS Pathog. 8, e1002661.
Park, K., and Scott, A.L. (2010). Cholesterol 25-hydroxylase production by
dendritic cells and macrophages is regulated by type I interferons.
J. Leukoc. Biol. 88, 1081–1087.
Pezacki, J.P., Sagan, S.M., Tonary, A.M., Rouleau, Y., Be´langer, S., Supekova,
L., and Su, A.I. (2009). Transcriptional profiling of the effects of 25-hydroxycho-
lesterol on human hepatocyte metabolism and the antiviral state it conveys
against the hepatitis C virus. BMC Chem. Biol. 9, 2.
Plemper, R.K. (2011). Cell entry of enveloped viruses. Curr Opin Virol 1,
92–100.
Rasheed, S., Yan, J.S., Lau, A., and Chan, A.S. (2008). HIV replication en-
hances production of free fatty acids, low density lipoproteins and many key
proteins involved in lipid metabolism: a proteomics study. PLoSONE 3, e3003.
Sadler, A.J., and Williams, B.R. (2008). Interferon-inducible antiviral effectors.
Nat. Rev. Immunol. 8, 559–568.
Sainz, B., Jr., Barretto, N., Martin, D.N., Hiraga, N., Imamura, M., Hussain, S.,
Marsh, K.A., Yu, X., Chayama, K., Alrefai, W.A., and Uprichard, S.L. (2012).
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor
as a new hepatitis C virus entry factor. Nat. Med. 18, 281–285.
Samuel, C.E. (2001). Antiviral actions of interferons. Clin. Microbiol. Rev. 14,
778–809.
Schoggins, J.W., Wilson, S.J., Panis, M., Murphy, M.Y., Jones, C.T., Bieniasz,
P., and Rice, C.M. (2011). A diverse range of gene products are effectors of the
type I interferon antiviral response. Nature 472, 481–485.
Seo, J.Y., Yaneva, R., and Cresswell, P. (2011). Viperin: amultifunctional, inter-
feron-inducible protein that regulates virus replication. Cell Host Microbe 10,
534–539.
Sheridan, D.A., Neely, R.D., and Bassendine,M.F. (2013). Hepatitis C virus and
lipids in the era of direct acting antivirals (DAAs). Clin Res Hepatol Gastroen-
terol 37, 10–16.
St Vincent, M.R., Colpitts, C.C., Ustinov, A.V., Muqadas, M., Joyce, M.A.,
Barsby, N.L., Epand, R.F., Epand, R.M., Khramyshev, S.A., Valueva, O.A.,
et al. (2010). Rigid amphipathic fusion inhibitors, small molecule antiviral
compounds against enveloped viruses. Proc. Natl. Acad. Sci. USA 107,
17339–17344.
Stebbing, J., Gazzard, B., Kim, L., Portsmouth, S., Wildfire, A., Teo, I., Nelson,
M., Bower, M., Gotch, F., Shaunak, S., et al. (2003). The heat-shock protein
receptor CD91 is up-regulated in monocytes of HIV-1-infected ‘‘true’’ long-
term nonprogressors. Blood 101, 4000–4004.
Tam, V.C., Quehenberger, O., Oshansky, C.M., Suen, R., Armando, A.M.,
Treuting, P.M., Thomas, P.G., Dennis, E.A., and Aderem, A. (2013). Lipidomic
profiling of influenza infection identifies mediators that induce and resolve
inflammation. Cell 154, 213–227.
Teissier, E., and Pe´cheur, E.I. (2007). Lipids asmodulators of membrane fusion
mediated by viral fusion proteins. Eur. Biophys. J. 36, 887–899.
Teissier, E., Zandomeneghi, G., Loquet, A., Lavillette, D., Lavergne, J.P., Mon-
tserret, R., Cosset, F.L., Bo¨ckmann, A., Meier, B.H., Penin, F., and Pe´cheur,
E.I. (2011). Mechanism of inhibition of enveloped virus membrane fusion by
the antiviral drug arbidol. PLoS ONE 6, e15874.
Vigant, F., Lee, J., Hollmann, A., Tanner, L.B., Akyol Ataman, Z., Yun, T., Shui,
G., Aguilar, H.C., Zhang, D., Meriwether, D., et al. (2013). A mechanistic para-
digm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog.
9, e1003297.
Walsh, E.E. (2012). Statins and influenza: can we move forward? J. Infect. Dis.
205, 1–3.
Wilkins, C., Woodward, J., Lau, D.T., Barnes, A., Joyce, M., McFarlane, N.,
McKeating, J.A., Tyrrell, D.L., and Gale, M., Jr. (2013). IFITM1 is a tight junction
protein that inhibits hepatitis C virus entry. Hepatology 57, 461–469.
Wolf, M.C., Freiberg, A.N., Zhang, T., Akyol-Ataman, Z., Grock, A., Hong,
P.W., Li, J., Watson, N.F., Fang, A.Q., Aguilar, H.C., et al. (2010). A broad-
spectrum antiviral targeting entry of enveloped viruses. Proc. Natl. Acad.
Sci. USA 107, 3157–3162.
Cell Host & Microbe
Short ReviewYount, J.S., Karssemeijer, R.A., and Hang, H.C. (2012). S-palmitoylation and
ubiquitination differentially regulate interferon-induced transmembrane pro-
tein 3 (IFITM3)-mediated resistance to influenza virus. J. Biol. Chem. 287,
19631–19641.
Zasloff, M., Adams, A.P., Beckerman, B., Campbell, A., Han, Z., Luijten, E.,
Meza, I., Julander, J., Mishra, A., Qu, W., et al. (2011). Squalamine as abroad-spectrum systemic antiviral agent with therapeutic potential. Proc.
Natl. Acad. Sci. USA 108, 15978–15983.
Zhao, H., Lin, W., Kumthip, K., Cheng, D., Fusco, D.N., Hofmann, O., Jilg, N.,
Tai, A.W., Goto, K., Zhang, L., et al. (2012). A functional genomic screen re-
veals novel host genes thatmediate interferon-alpha’s effects against hepatitis
C virus. J. Hepatol. 56, 326–333.Cell Host & Microbe 14, October 16, 2013 ª2013 Elsevier Inc. 385
